Vardenafil is an inhibitor of phosphodiesterase 5 (PDE5) used for the treatment of impotence (erectile dysfunction) marketed by Bayer Pharmaceuticals and GlaxoSmithKline under the Levitra, Vivanza and Staxyn names.
Vardenafil was marketed in 2003 and Bayer Pharmaceuticals and GlaxoSmithKline under the name Levitra. After his sales managed to obtain a significant market share versus Viagra, the first pill to treat erectile dysfunction produced by Pfizer and Cialis from Eli Lilly and Company.1 In 2005, co-promotion rights of GSK on Levitra returned to Bayer in many markets outside the United States. Both companies sell the product in Italy: Bayer as Levitra and GSK under the name Vivanza.
In 2010 a new orally soluble formulation of Levitra, sold as Staxyn was approved in the United States. The following year, Staxyn was also introduced in Canada. In Europe it is marketed as Levitra-orodispersible.
Vardenafil inihibición acts by phosphodiesterase 5 (PDE5) which is the enzyme responsible for degradation of cGMP nucleic acid. By increasing the concentration of this molecule causes smooth muscle relaxation and the rush of blood to the corpora cavernosa of the penis.
Vardenafil indications and contraindications are the same as those of other phosphodiesterase 5, having very similar to sildenafil citrate (Viagra) and tadalafil (Cialis) features. Structurally, the difference between the molecule of vardenafil and sildenafil citrate is a position other than the nitrogen atom and the change ring methyl group to an ethyl group piperazine. Tadalafil is structurally different chemical level of the previous two. The short time to onset of effect is significantly different from sildenafil, which takes longer to start clinical effect.
Besides used to treat erectile dysfunction, vardenafil can also prevent premature ejaculation.